VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Intuitive Surgical, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisIntuitive Surgical, Inc.
ISRG · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Intuitive Surgical, Inc.'s moat claims, evidence, and risks.
View ISRG analysisComparison highlights
- Moat score gap: Intuitive Surgical, Inc. leads (83 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Intuitive Surgical, Inc. has 3 segments (60.8% in Instruments and Accessories).
- Primary market structure: Oligopoly vs Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Intuitive Surgical, Inc. has 9 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Intuitive Surgical, Inc.
Instruments and Accessories
Proprietary robotic surgery instruments, accessories, and consumables used per procedure on the da Vinci (and Ion) installed base
Global
Hospitals and surgery centers purchasing consumables; surgeons and OR teams as end users
Consumables OEM within proprietary platform
60.8%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Intuitive Surgical, Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Intuitive Surgical, Inc. segments
Full profile >Systems
Quasi-Monopoly
Instruments and Accessories
Monopoly
Services
Monopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.